BS_KX6J8TRK
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 167.44415243101182
- age_years
- 2.934
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_FJZPQZ2C | pleomorphic xanthoastrocytoma(PXA) | — | 0.927 |
| 2 | SRR5088929 | — | — | 0.925 |
| 3 | BS_24AHZ9ZW | low-grade glioma | — | 0.920 |
| 4 | BS_KXH37MPN | DNET | — | 0.918 |
| 5 | BS_D3YBV7KB | low-grade glioma | — | 0.915 |
| 6 | BS_Z0AVVB1V | pilocytic astrocytoma | — | 0.912 |
| 7 | BS_8VAZSJEN | pilocytic astrocytoma | — | 0.908 |
| 8 | SRR1459211 | GTEX | — | 0.907 |
| 9 | 74cffe84-dca8-4673-925a-9e0d6344832a | — | — | 0.902 |
| 10 | BS_T55Y4Z0Y | low-grade glioma | — | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.636 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.622 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.598 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.562 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.561 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.498 | Inavolisib | — uncovered |
| COMPLEMENT | 0.471 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.444 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.430 | Idelalisib | — uncovered |
| COAGULATION | 0.422 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.393 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.388 | Inavolisib | — uncovered |
| APOPTOSIS | 0.351 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.343 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.327 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.298 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.290 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.287 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.282 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |